OncoMatch/Clinical Trials/NCT04539977
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
Is NCT04539977 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including TQB2450 and TQB2450 for small-cell lung cancer.
Treatment: TQB2450 · TQB2450 — This is a non-randomized, open-label, single-center, phase II trial to evaluate the safety and effectiveness of surgery or radiotherapy after PD-L1 inhibitor (TQB2450) and chemotherapy induction therapy followed by maintenance therapy as first-line treatment in patients limited-stage SCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV, III, LOCAL ADVANCED
extensive stage or limited stage (local advanced) confirmed by imageological examinations.
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic anti-cancer treatment
Participants who have received any systemic anti-cancer treatment for SCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment
Cannot have received: Chinese medicine against cancer
Administration of any Chinese medicine against cancer before administration of the drug
Lab requirements
Blood counts
ANC count ≥1.5×10^9/L, platelet count ≥100×10^9/L, hemoglobin ≥90 g/L; INR and PT < 1.5×ULN; APTT ≤1.5×ULN
Kidney function
Liver function
total bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN, or ≤5×ULN with liver metastatic tumor
Patients with good function of other main organs (liver, kidney, blood system, etc.): * ANC count ≥1.5×10^9/L, platelet count ≥100×10^9/L，hemoglobin ≥90 g/L; * the international standard ratio of prothrombin time (INR) and prothrombin time (PT) < 1.5 times of upper limit of normal (ULN); * partial thromboplastin time (APTT) ≤1.5×ULN; * total bilirubin ≤1.5×ULN; * alanine aminotransferase (ALT) aspartate aminotransferase (AST) ≤2.5×ULN, or ALT and AST ≤5×ULN in the patients with liver metastatic tumor.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04539977 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IV or III or LOCAL ADVANCED is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages